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Atherosclerosis is the number one cause of death in the Western world. It results
from the interaction between modified lipoproteins and cells such as macrophages,
dendritic cells (DCs), T cells, and other cellular elements present in the arterial wall.
This inflammatory process can ultimately lead to the development of complex lesions, or
plaques, that protrude into the arterial lumen. Ultimately, plaque rupture and thrombosis
can occur leading to the clinical complications of myocardial infarction or stroke. Although
each of the cell types plays roles in the pathogenesis of atherosclerosis, the focus of
this review will be primarily on the macrophages and DCs. The role of these two cell
types in atherosclerosis is discussed, with a particular emphasis on their involvement in
atherosclerosis regression.
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MACROPHAGES AND ATHEROSCLEROSIS
Atherosclerosis, a chronic inflammatory disease that occurs
within the artery wall, is one of the underlying causes of vas-
cular complications such as myocardial infarction, stroke, and
peripheral vascular disease. Atherogenesis is a process that occurs
over many years with the initiation phase being the suben-
dothelial accumulation of apolipoprotein B-containing lipopro-
teins (ApoB) (Williams and Tabas, 1995; Glass and Witztum,
2001; Williams et al., 2007, 2008). These particles undergo mod-
ifications, including oxidation and hydrolysis, leading to the
activation of endothelial cells. These cells secrete chemoattac-
tants called chemokines that interact with specific receptors
expressed on monocytes essentially “recruiting” the cells into
the lesion. The monocytes then roll along the endothelial cells
via interactions of specific selectins, [i.e., P-selectin glycoprotein
ligand-1 (PSGL-1)] with attachment being mediated by mono-
cyte integrins such as very late antigen-4 (VLA-4) and lymphocyte
function-associated antigen 1 (LFA-1) to the respective endothe-
lial ligands vascular cell adhesion molecule-1 (VCAM-1) and
intercellular adhesionmolecule-1 (ICAM-1) (Glass andWitztum,
2001; Mestas and Ley, 2008). Once attached, a process called dia-
pedesis occurs by whichmonocytes enter the subendothelial space
(Kamei and Carman, 2010). Having accessed the subendothelial
space, recruited monocytes differentiate into macrophages, a pro-
cess driven by interactions with the extracellular matrix (ECM)
and cytokines, including macrophage colony-stimulating factor
and members of the tumor necrosis factor family (Johnson and
Newby, 2009). The uptake of oxidized LDL by the macrophages
occurs via scavenger receptors, notably the type A scavenger
receptor (SRA) and CD36, a member of the type B family
(Kunjathoor et al., 2002). Interestingly, deletion of SRA or CD36
doesn’t ameliorate plaque development suggesting that other
mechanisms must be present (Moore et al., 2005; Goyal et al.,
2012). Indeed, fluid phased pinocytosis was shown to play a role
in foam cell formation (Kruth et al., 2005)
The cholesteryl esters of the apoB particles that are ingested
are hydrolyzed into free cholesterol, which occurs in late endo-
somes. The free cholesterol is then delivered to the endoplasmic
reticulum (ER) where it is re-esterified by acyl-CoA: choles-
terol ester transferase (ACAT) (Maxfield and Tabas, 2005). It is
this process that leads to the macrophages having the “foamy”
appearance. Data from in vivo studies indicate that the form of
ACAT in macrophages, ACAT1, contributes to foam cell forma-
tion in the arterial wall and the development of atherosclerosis.
Studies in apoE−/− mice, however, have suggested that com-
plete deficiency of ACAT1 activity is not anti-atherogenic, in
part because of toxicity resulting from adverse effects on tissue
cholesterol homeostasis (Rudel et al., 2001). Hence it was tested
whether partial inhibition of ACAT1 and ACAT2 (expressed in
liver and intestine) activities reduces atherosclerosis develop-
ment in apoE-deficient mice and avoids toxicity. Indeed, par-
tial inhibition led to a reduction in atherosclerosis (Kusunoki
et al., 2001). In order to extend these studies in humans, a
prospective, randomized, double-blind, placebo-controlled study
(Carotid Atherosclerosis Progression Trial Investigating Vascular
ACAT Inhibition Treatment Effects [CAPTIVATE]) was designed.
It included 892 patients heterozygous for familial hypercholes-
terolemia. Interestingly, pactimibe (ACAT inhibitor) had no effect
on atherosclerosis as assessed by changes in maximum carotid
intima-media thickness (CIMT) compared with placebo but was
actually associated with an increase in mean CIMT as well as
increased incidence of major cardiovascular events (Meuwese
et al., 2009). Whether these results were truly due to this spe-
cific compound or is a class effect is not entirely known. Future
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investigative work will need to be performed in order to deter-
mine whether there is a future in ACAT inhibitors as therapies
against plaque formation.
It is well-known that macrophages contribute to formation
of the necrotic core and fibrous cap thinning that characterizes
the vulnerable plaque (Virmani et al., 2002a,b; Tabas, 2010a).
How do these macrophages ultimately contribute to the vul-
nerable plaque? Macrophage-derived matrix metalloproteinases
(MMPs) are a family of proteins that can degrade various types of
ECM and hence promote rupture. Moreover, once activated, cer-
tain MMPs can activate other ones (Tabas, 2010a). Studies have
shown a temporal and spatial correlation between the presence of
macrophages in rupture-prone shoulder regions of plaques, thin-
ning of the fibrous cap in these regions, and local accumulation
of activated MMPs, especially MMP-2 and MMP-9 (Galis et al.,
1994). Since mouse models of atherosclerosis do not recapitulate
plaque rupture, investigations have focused on endpoints such
as lesion area or plaque collagen content. For example, increases
in plaque collagen were observed when MMP-13 or MMP-14
were deleted globally or in macrophages (Deguchi et al., 2005;
Schneider et al., 2008). In a study that attempted to look directly
at plaque disruption, macrophage over-expression of wild-type
(WT) MMP-9 did not lead to a phenotype (plaque fissuring)
in apoE−/− deficient mice due to a lack of MMP activation in
plaques, but over-expression of a constitutively active mutant
form of MMP-9 resulted in plaque fissuring (Gough et al., 2006).
New mouse models of true plaque rupture will be needed in
order to validate these concepts and help guide whether MMP
inhibition in humans is a worthwhile strategy.
Another potential mechanism of how macrophages may pro-
mote plaque thinning and increase vulnerability is via causing
smooth muscle cell (SMC) apoptosis. Vulnerable plaques show
evidence of SMC death and decreased numbers of SMCs. In vitro
data show that macrophages can trigger apoptosis in SMCs by
activating their Fas apoptotic pathway as well as by secreting pro-
apoptotic TNFα and nitric oxide (Boyle et al., 2003). Studies
demonstrated that in regions of vulnerable plaques that have
defective clearance of apoptotic cells, macrophage secretion of
TGFβ may be decreased hence depriving neighboring SMCs of
this important inducer of collagen synthesis (Fadok et al., 1998).
Even after plaque rupture, the macrophage continues to play a
role as it secretes prothrombotic tissue factor thereby accelerating
thrombus formation (Glass and Witztum, 2001; Williams et al.,
2007, 2008).
Another critical feature of vulnerable plaques is the necrotic
core. Necrotic cores arise from the combination of apopto-
sis of advanced lesional macrophages and defective phago-
cytic clearance (efferocytosis) of the apoptotic macrophages
in advanced plaques (Tabas, 2010a). Studies have shown that
necrotic cores contribute to inflammation, thrombosis, prote-
olytic plaque breakdown, and physical stress on the fibrous cap
(Virmani et al., 2002a,b; Tabas, 2010a). Growth factor depri-
vation, oxidative stress, and death receptor activation by lig-
ands are likely processes that contribute to macrophage death
in advanced atheromata. Recent studies, in vivo, have recently
shown that prolonged activation of ER stress pathways, pri-
marily the unfolded protein response (UPR), contributes to
macrophage death and subsequent plaque necrosis in advanced
atheromata (Tabas, 2010b, 2011; Tabas and Ron, 2011). It is
important to note that macrophage apoptosis by itself will not
trigger plaque necrosis. Rather, plaque necrosis results when
apoptotic macrophages are not sufficiently cleared by phagocytes
(Tabas, 2010a). Efferocytosis of apoptotic macrophages is impor-
tant because it leads to protective effects such as clearing the
cells before membrane damage leads to leakage of toxic intracel-
lular material. Several possible mechanisms might contribute to
defective efferocytosis, such as oxidative stress-induced efferocyte
death resulting from defective cholesterol efflux after apoptotic
cell engulfment and protease-mediated cleavage of the efferocyto-
sis receptorMerTK (Sather et al., 2007; Yvan-Charvet et al., 2010).
Additional studies will need to be performed in order to further
dissect the mechanisms involved.
It has previously been shown that there is macrophage het-
erogeneity in atherosclerotic plaques and both M1 as well
as M2 macrophages have been shown to exist in atheroscle-
rotic lesions (Bouhlel et al., 2007; Johnson and Newby, 2009).
Polarized activated M1 macrophages are induced by interferon-
gamma (IFN-γ) alone or in concert with microbial stimuli
such as lipopolysaccharide (LPS). M1 cells have an interleukin
IL-12high, IL-23high, IL-10low phenotype and are proficient pro-
ducers of effector molecules such as reactive oxygen and nitro-
gen intermediates. In addition, M1 cells produce inflammatory
cytokines and contribute as inducer and effector cells in polar-
ized Th1 responses. In contrast, the alternative M2 form of
macrophage activation is a generic name used for various forms of
non-classically activated macrophages (anti-inflammatory class)
resulting from cell exposure to IL-4 or IL-13, immune complexes,
IL-10, glucocorticoid, or secosteroid (vitamin D3) hormones. The
various forms of M2 macrophages share an IL-12low and IL-
23low phenotype as well as generally displaying high levels of
scavenger, mannose, and galactose-type receptors. Importantly,
arginine metabolism is shifted to the production of ornithine
and polyamines via arginase. In other words, M1 macrophages
are potent effector cells that produce primarily proinflammatory
cytokines, such as tumor necrosis factor-alpha (TNF-α), IL-6, and
IL-12. In contrast, M2 macrophages dampen these inflammatory
responses by producing anti-inflammatory factors such as IL-
10, transforming growth factor-beta (TGF-β), and IL-1 receptor
antagonist (IL-1Ra) (Mantovani et al., 2002, 2005).
DENDRITIC CELLS AND ATHEROSCLEROSIS
It is now well accepted that atherosclerosis is a chronic disease
of the arterial wall involving both innate and adaptive immu-
nity (Dumitriu and Kaski, 2011). Dendritic cells (DCs) are a
heterogeneous population of bone marrow-derived immune cells
that specialize in capturing, processing and presenting antigens
to T lymphocytes in order to induce and control immunity.
DCs are morphologically characterized by the presence of several
thin cytoplasmic processes (dendrites) and by large cytoplas-
mic veils that are continuously extended and retracted. DCs are
very efficient at internalizing antigens either by phagocytosis or
by receptor-mediated endocytosis. Subsequently, DCs display a
fragment of the antigen, bound to a class II major histocom-
patibility complex (MHC), on their membrane. CD4+ T cells
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recognize the antigen-class II MHCmolecule complex on the DC
membrane. DCs then produce a co-stimulatory signal such as
B7-1 or B7-2 ultimately activating the CD4+ T cells (Banchereau
and Steinman, 1998; Mallat et al., 2009; Koltsova and Ley, 2011;
Manthey and Zernecke, 2011; Van Vre and Bult, 2011; Van Vre
et al., 2011).
It is important to note that DCs are actually present in healthy
arteries and have been documented in the subendothelial space
and at the media-adventitia junction (Ma-Krupa et al., 2004;
Pryshchep et al., 2008). The localization of DCs adjacent to the
vasa vasorum allows for the monitoring of important access
pathways to the vessel wall, to present autoantigens such as oxi-
dized LDL – CD4+ T cells, and to locally initiate inflammatory
responses (Ma-Krupa et al., 2004; Pryshchep et al., 2008; Niessner
and Weyand, 2010). Interestingly, DCs and T cells are arrayed in
clusters that primarily locate to the shoulder and rupture prone
regions of the plaque (Yilmaz et al., 2004; Bobryshev, 2005; Erbel
et al., 2007). Importantly, it has been shown that patients with
angina and acute MI have reduced circulating blood-derived DC
precursors. In fact, blood derived DCs and plasmacytoid DCs
are actually diminished in patients with angiographically docu-
mented CAD potentially due to increased recruitment to plaques
(Van Vre et al., 2006; Yilmaz et al., 2006; Van Vre et al., 2010).
The identification of DCs in the arteries of animal mod-
els has facilitated the investigation of the impact of DCs in
atherosclerosis (Bobryshev et al., 1999, 2001; Ozmen et al., 2002).
Increased numbers of DCs have been observed in atheroscle-
rotic lesions in mouse models of atherosclerosis (Galkina et al.,
2006; Liu et al., 2008; Weber et al., 2011). Ludewig et al were
the first to report a link between immune-mediated arterial
inflammation and cholesterol-induced atherosclerosis mediated
by DCs in a hypercholesterolemic transgenic mouse model using
the defined expression of the microbial antigen β-galactosidase
(β-gal) in arterial SMCs in apoE−/− mice. Experimentation
revealed that hypercholesterolemia selectively enhanced and per-
petuated arterial inflammation. Furthermore, arterial inflamma-
tion significantly increased the susceptibility of the arterial wall to
cholesterol-dependent atherosclerosis (Ludewig et al., 2000).
It was also demonstrated that dyslipidemia associated
with atherosclerotic disease alters DC function: hyperlipidemia
inhibits DCmigration with HDL restoring it (Angeli et al., 2004).
DCs can maintain antigen-processing and antigen-presenting
capabilities, which allow them to efficiently prime CD4+ T cells
under hypercholesterolemic conditions (Packard et al., 2008).
Studies demonstrated that the peroxisome proliferator activated
receptor gamma (PPAR-γ agonist ciglitazone inhibited the ox-
LDL-induced maturation and immune functions of DCs (Luo
et al., 2004). Interestingly, it was shown that the PPAR-α agonist
fenofibrate, inhibited the ox-LDL-induced immune maturation
of DCs (Shi et al., 2008). These effects of PPARs may par-
tially explain their ability to slow atherosclerosis progression and
reduce the risk of coronary heart disease independently from their
metabolic effects.
Statins, HMG–CoA reductase inhibitors, are a mainstay in
the treatment of hyperlipidemia. Studies have shown that these
agents also possess powerful pleiotropic effects that are indepen-
dent of their cholesterol lowering properties. The major effect
of statins is the inhibition of cholesterol and isoprenoid syn-
thesis, which ultimately results in upregulation of endothelial
nitric oxide synthase (eNOS), an enzyme responsible for vascu-
lar endothelial function (Liao, 2002). Additionally, antioxidant
effects (i.e., via the decreased production of NADPHoxidase) lead
to decreased amounts of reactive oxidant species in the circulation
(Endres, 2005). Inflammatory markers such as C-reactive protein
(CRP) and nuclear factor κB (NF-κB) have also been shown to be
reduced by statins, leading to the hypothesis that statins possess
anti-inflammatory properties (Li et al., 2010). Other proposed
mechanisms include immunomodulation, normalization of sym-
pathetic outflow, plaque stabilization, decreased activation of the
blood coagulation cascade, and inhibition of platelet aggregation
(Mihos and Santana, 2011). Pre-incubation of lipolysaccharide-
stimulated DCs with statins significantly suppressed secretion
of proinflammatory cytokines as well as the ability to induce
T cell proliferation and activation (Yilmaz et al., 2006). Another
study provided clinical evidence that atorvastatin at 20mg/day for
four weeks significantly reduce DCs andmatrix metalloproteinase
expression in the aortic wall of patients undergoing abdominal
aorta replacement (Kajimoto et al., 2009). These results suggest
yet another pleiotropic effects of statins that may be independent
of its lipid-lowering effects.
Eicosapentaenoic acid (EPA), another agent known to pos-
sess beneficial effects in cardiovascular disease, has recently been
shown to promote regression of atherosclerotic lesions. The data
suggests that this was in part due to the ability of the com-
pound to modulate DCs. Flow cytometric analysis revealed that
EPA increased immature DCs [CD11c(+) CD80(−) CD86(−)],
increased the indoleamine 2,3-dioxygenase (IDO) in DCs, and
decreased the number of CD4+ T cells. Importantly, in the pres-
ence of an IDO inhibitor (1-methyl-dl-tryptophan), the beneficial
effects of EPA on regression were inhibited, suggesting that the
effect of EPA was mainly mediated through IDO (Nakajima et al.,
2011).
Interestingly, DCs were shown to be present in human unsta-
ble plaques (Yilmaz et al., 2004) and higher DC densities were
found in carotid plaques from symptomatic patients as compared
to those from asymptomatic patients (Kawahara et al., 2007). DCs
were also described in human symptomatic in-stent restenosis
(Skowasch et al., 2003) and in aortic aneurysms (Bobryshev et al.,
1998). The above studies suggest that the presence of DCs is asso-
ciated with progression of atherosclerosis. However, a study by
Gautier and colleagues suggests that there is more to the role
of DCs that may have been previously appreciated. They cre-
ated a mouse model in which the lifespan and immunogenicity
of DCs were enhanced by specific over-expression of the human
antiapoptotic gene B-cell lymphoma 2 (hBcl-2) under the con-
trol of the CD11c promoter (Gautier et al., 2009). In either LDL
receptor-deficient or apolipoprotein E-deficient backgrounds,
DC-hBcl2 mice exhibited an expanded DC population associ-
ated with enhanced T-cell activation, a Th1 and Th17 cytokine
expression profile, as well as elevated production of Th1-driven
IgG2c autoantibodies directed against oxidation-specific epi-
topes. However, expansion of the DC population was unexpect-
edly associated with a decrease in plasma cholesterol levels and
no acceleration of atherosclerotic plaque progression. Conversely,
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depletion of DCs in hyperlipidemic CD11c-diphtheria toxin
receptor/apolipoprotein E-deficient transgenic mice resulted in
enhanced hypercholesterolemia, thereby arguing for a close
relationship between the DC population and plasma choles-
terol levels (Gautier et al., 2009). These studies demonstrate
that DCs are central to the atherosclerotic process by being
directly implicated in both cholesterol homeostasis and immune
response.
There are various types of DCs with distinct roles. For exam-
ple, unlike conventional DCs, plasmacytoid DCs (PDC) are poor
in antigen presentation and critical for type I interferon response.
A recent study sheds light on the possible role that PDCs may
exhibit. Administration of 120G8mAb (antibody which recog-
nizes PDCA-1 also referred to as bone marrow stromal cell
antigen 2 [BST2], a marker specifically expressed onmouse PDCs
(Blasius et al., 2006)) in LDLR−/− mice led to PDC depletion
resulting in plaque T-cell accumulation and enhanced plaque pro-
gression. The authors concluded that PDCs may play a protective
role in atherosclerosis, possibly by dampening T-cell proliferation
and activity in peripheral lymphoid tissue (Daissormont et al.,
2011). Further work will be required in order to determine the
therapeutic potential in modulating DC biology for the treatment
of atherosclerosis.
ATHEROSCLEROSIS REGRESSION
The idea that human atheromata can regress at all is some-
thing that met considerable resistance over the years. The reason
for this may have been that advanced atherosclerotic lesions in
humans and in animal models contain calcification and fibro-
sis, characteristics that seem irreversible (Blankenhorn andHodis,
1994; Williams et al., 2007, 2008). Regardless, the ability to
induce atherosclerosis regression is a desirable clinical goal. The
first interventional study demonstrating substantial shrinkage of
atherosclerotic lesions was performed in cholesterol-fed rabbits
over 50 years ago (Friedman et al., 1957). Animals received intra-
venous bolus injections of phosphatidylcholine (PC). After less
than a week and a half of treatment, the remaining plaques were
fewer and much smaller than initially with approximately 75%
of the arterial cholesterol stores being removed. Using a variety
of atherosclerotic animal models, other groups showed similar
arterial benefits from the injection of dispersed phospholipids
(Williams et al., 1984; Stein and Stein, 2001).
Armstrong and colleagues found that advanced arterial lesions
in cholesterol-fed rhesus monkeys underwent shrinkage and
remodeling during long-term follow-up after a switch to low-fat
or linoleate-rich diets (Armstrong et al., 1970; Armstrong, 1976).
The subsequent regression period (lasted 40 months) resulted in
the loss of approximately two-thirds of coronary artery choles-
terol, substantial reduction in necrosis, improvement in extracel-
lular lipid levels and fibrosis, as well as lesion shrinkage. Success
in atherosclerosis regression was again achieved in rabbits in
1976, following reversion to a normal-chow diet in combination
with the administration of hypolipidemic agents (Wissler and
Vesselinovitch, 1976). Decades later, a series of studies achieved
shrinkage of atheromata in rabbits via injections of HDL or HDL-
like apolipoprotein A-I (apoA-I) and PC disks (Miyazaki et al.,
1995).
In spite of the clinical desirability to achieve regression,
research into the factors that may be mediating this process has
been hampered by the scarcity of appropriate animal models. The
relative ease of progression studies, using apoE−/− or LDLR−/−
mice, has led to an emphasis on this phase of the disease process,
but this emphasis also highlights the relative dearth of models
of regression. The similarities between atherosclerosis in humans
andmice deficient either in apoE (Plump et al., 1992; Zhang et al.,
1992; Nakashima et al., 1994; Breslow, 1996) or the LDL receptor
(Ishibashi et al., 1993) suggest that molecular mechanisms under-
lying regression in these mouse models could be relevant to the
reduction in plaque burden in the human population (Williams
et al., 2007, 2008; Feig et al., 2009).
Plaque regression in mouse models of atherosclerosis has
previously been demonstrated primarily by somatic adenoviral
gene transfer (Yang et al., 1996; DeMatteo et al., 1997). Such
approaches have been limited mainly because of the eventual loss
of transgene expression, even with second-generation viral vec-
tors, likely caused by immune responses directed against both
the transgene product and adenoviral proteins. A new regres-
sion model was introduced which involves transplantation of
either a thoracic aortic segment (Reis et al., 2001) or an aortic
arch segment (Chereshnev et al., 2003) from apoE−/− mice into
WT recipient mice. Under the conditions of the WT mouse in
which the dyslipidemia is corrected, regression is rapidly appar-
ent (as judged by plaque CD68+ monocyte derived cell content).
However, when the recipient is an apoE−/− mouse, further pro-
gression is evident (Chereshnev et al., 2003; Llodra et al., 2004;
Trogan et al., 2004, 2006). Using laser capture microdissection of
CD68+ cells in the lesions, it was demonstrated that regression
was characterized by the decrease in expression of inflammation-
related genes such as VCAM-1, ICAM-1, monocyte chemotactic
protein-1 (MCP-1), and TNF-α (Trogan et al., 2006). Interestingly
the nuclear transcription factors liver X receptor alpha (LXRα),
liver X receptor beta (LXRβ), and their downstream targets ATP-
binding cassette transporter 1 (ABCA1) as well as ATP-binding
cassette sub-family G member 1 (ABCG1) were upregulated in
these same cells (Trogan et al., 2006).
Notably, the decrease in foam cell content was attributed to
emigration of these cells from plaques to regional and systemic
lymph nodes under regression, but not progression, conditions
(Llodra et al., 2004; Trogan et al., 2006). The emigrating cells
expressed markers of macrophages (such as CD68 and CD115)
andDCs (such as CD11c) (Llodra et al., 2004; Trogan et al., 2006).
Since migration of DCs to lymph nodes absolutely requires the
chemokine receptor CCR7 (Forster et al., 1999), we hypothesized
that it became induced in foam cells under regression conditions.
Indeed, we found an increase in CCR7mRNA and protein expres-
sion only in foam cells from the regression environment (Trogan
et al., 2006) and showed the functional requirement of CCR7 for
regression in our transplant model (Trogan et al., 2006). We then
determined that LXR is required for maximal effects on plaque
CD68+ cell expression of CCR7 as well as monocyte-derived cell
egress during atherosclerosis regression inmice (Feig et al., 2010).
The induction of CCR7 is likely also related to the lipid milieu.
This idea is in agreement with two recent reports. In the first,
scientists demonstrated that loading THP-1 human monocytes
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with oxidized LDL suppresses the expression of CCR7 (Damas
et al., 2007). In the second, it was reported that CCR7 expression
was significantly downregulated in human carotid atherosclerotic
plaques (Nickel et al., 2012). Using bioinformatics, we have iden-
tified potential sterol response elements (SREs) in the promoter
region of CCR7 (Feig et al., 2011). We have found that statins,
potent regulators of SRE-dependent transcription can induce
CCR7 expression in vivo and promote regression via emigration
of CD68+ cells in a CCR7 dependent manner (Feig et al., 2011).
It was recently reported that both atorvastatin and rosuvastatin
can promote regression of atherosclerosis as assessed by intravas-
cular ultrasound (IVUS) (Nicholls et al., 2011). Our data suggests
that activation of the CCR7 pathway may be one mechanism to
explain how this may occur.
Although HDL has been shown to reduce atherosclerosis pro-
gression in mouse-based studies (Rubin et al., 1991; Rong and
Fisher, 2000; Choudhury et al., 2004; Feig et al., 2008), its role
in regression is also of great interest because of the important
clinical implications. Badimon and colleagues attracted consid-
erable attention in 1990 by showing regression of atherosclerotic
lesions by infusions of theHDLplasma fraction in the cholesterol-
fed rabbit (Badimon et al., 1990). Later studies demonstrated
that intravenous infusion of apoAI and liver-directed adenoviral
transfer of apoAI DNA led to plaque regression (Miyazaki et al.,
1995; Tangirala et al., 1999). The rapidity of the regression process
has been seen in that the infusion of recombinant apoAI milano
(a natural mutant of human apoAI thought to be more effective
in promoting reverse cholesterol transport) into apoE−/− mice
resulted in reductions in lipid and macrophage content of the
lesions just after 48 h (Shah et al., 2001).
A limitation to examining directly the effects of HDL has
been the difficulty in sustaining the elevation of HDL. Using
our transplant model, we were able to tackle this issue (Rong
et al., 2001; Feig et al., 2011). In our more recent study (Feig
et al., 2011), plaque-bearing aortic arches from apolipoprotein
E-deficient mice (low HDL-C, high non-HDL-C) were trans-
planted into recipient mice with different levels of HDL-C and
non-HDL-C: C57BL6 mice (normal HDL-C, low non-HDL-C),
apoAI−/− mice (low HDL-C, low non-HDL-C), or apoE−/−
mice transgenic for human apoAI [hAI/apoE−/−] (normal HDL-
C, high non-HDL-C). Remarkably, despite persistent elevation
of non-HDL-C in hAI/apoE−/− recipients, plaque CD68+ cell
content decreased by >50% by one week after transplantation,
whereas there was little change in apoAI−/− recipient mice
despite hypolipidemia. Interestingly, the decreased content of
plaque CD68+ cells was associated with their emigration and
induction of their chemokine receptor CCR7 (Feig et al., 2011).
Furthermore, in CD68+ cells laser-captured from the plaques,
normalization of HDL-C led to decreased expression of inflam-
matory factors and enrichment of markers of the M2 (tissue
repair) macrophage state (Feig et al., 2011). These data empha-
sized the crucial role HDL may play in the regression process,
which is consistent with a recent meta-analysis of clinical stud-
ies in which it was shown that atherosclerosis regression (assessed
by IVUS) after LDL lowering was most likely to be achieved
when HDL was also significantly increased (Nicholls et al.,
2007).
To examine effects of HDL on plaque, infusion studies have
been performed in humans. Basically, high risk patients were
infused with either apoAI milano/phospholipid complexes (an
artificial form of HDL) or phospholipid complexes (control) once
a week for five weeks. Compared to the control group, by IVUS,
there was a 4.2% decline in atheroma volume in the treated group,
although there was no effect of a higher vs lower dose of the
HDL (Nissen et al., 2003). In another infusion study, reconsti-
tuted HDL containing wild type apoAI was infused into high risk
patients for six weeks. Although compared to the control group,
there was no difference in atheroma volume by IVUS, there were
statistically significant improvements in plaque characterization
index and coronary score on quantitative coronary angiography
(Tardif et al., 2007).
It is unlikely that regression of atherosclerosis occurs only
through one mechanism. A recent report showed that netrin-1,
a neuroimmune guidance cue, was secreted by macrophages in
human and mouse atheroma, where it inactivated the migration
of macrophages toward chemokines (such as chemokine [C-C
motif] ligand 19, ligand for CCR7 (Forster et al., 1999)) linked
to their egress from plaques. Interestingly, targeted deletion of
netrin-1 in macrophages resulted in much less atherosclerosis in
LDLR−/− and promoted the emigration of macrophages from
plaques (van Gils et al., 2012). These findings suggest that inhi-
bition of netrin-1 may be one method of inducing regression of
atherosclerosis. In contrast, Potteaux et al suggested that suppres-
sion of monocyte recruitment along with apoptosis accounted for
the decrease in macrophage content during the regression seen
with viral vector restoration of apoE in apoE−/− mice (Potteaux
et al., 2011). To begin addressing other possible mechanisms,
we decided to perform microarray experiments in which we
laser captured CD68+ foam cells from baseline, apoE−/− recip-
ients, and WT recipients. We were able to demonstrate that the
two major subsets of monocytes CCR2+CX3CR1+Ly-6Chi and
CCR2−CX3CR1+Ly-6Clo migrate out of lesions under regression
conditions. However, their regression is impaired under hyper-
lipidemic conditions. Not surprisingly, we found a distinct molec-
ular signature characterizing progression versus regression. When
the data was subjected to pathway analysis using specialized bioin-
formatic tools, we found that genes related to migratory capacity
like those that make up the contractile apparatus (actin and
myosin subunits) were significantly up-regulated under regres-
sion conditions. These results support our previous reports that
emphasized that regression is characterized by cells emigrating
out of plaques.
Consistently, among all samples tested, the most highly up-
regulated (∼14X) gene under regression conditions was arginase
I (ArgI). ArgI is a classical marker of the anti-inflammatory
M2 macrophage (Mantovani et al., 2002, 2005). Although we
are first to report that argI is differentially expressed under
regression of atherosclerosis (Feig et al., 2011), the idea is
supported by some studies in the literature. In macrophages,
L-arginine can be metabolized by NOS and arginase to form
NO and urea, respectively (Getz and Reardon, 2006). ArgI is
induced in a number of vascular cells, including endothelial
cells, SMCs, and macrophages by Th2 cytokines including IL-4,
IL-10, IL-13, and granulocyte macrophage colony-stimulating
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factor (Munder et al., 1999; Chang et al., 2000; Jost et al., 2003).
Teupser et al reported that peritoneal macrophages from an
atherosclerosis-prone strain of rabbits had lower levels of argI
expression (Teupser et al., 2006). To test the effect of argI over-
expression on atherosclerosis susceptibility, bone marrow from
argI-transgenic (expressing human argI under the control of a
CMV promoter) and non-transgenic animals were transplanted
into LDL-receptor deficient recipients. After 12 weeks of high fat
diet, animals were sacrificed. Importantly, there were no signifi-
cant differences in lipoprotein levels. However, atherosclerosis of
animals transplanted with transgenic bone marrow was signifi-
cantly reduced compared to controls. Hence, it was concluded
that argI might constitute an interesting novel target for the
prevention of atherosclerosis (Teupser et al., 2007). In addition,
the group led by Newby demonstrated that foam cell forma-
tion further lowers argI levels (Thomas et al., 2007). Whether
argI is protective against atherosclerosis simply by reducing nitric
oxide (NO) production is an unanswered question. However,
a wealth of evidence suggests that endothelial NO production
(from endothelial nitric oxide synthase [eNOS]) is protective
against atherosclerosis by, for example, causing vasodilatation,
reducing LDL oxidation, and reducing monocyte recruitment
to lesions (Landmesser et al., 2004). Macrophage NO produc-
tion (most actively from inducible nitric oxide synthase [iNOS])
is most likely harmful (Luoma et al., 1998; Boyle et al., 2002),
because iNOS knockout attenuates atherosclerosis in apoE−/−
mice (Detmers et al., 2000). It should be noted that there are
species differences in terms of macrophage NO production and
regulation. For example, murine macrophages produce large
amounts of NO and L-citrulline from L-arginine via induc-
tion of iNOS. Human macrophages exhibit iNOS activity, albeit
induced by other stimuli rather than those inducing nitrite pro-
duction in murine macrophages (Fang, 2004; Schneemann and
Schoeden, 2007). It is clear, though, that high levels of NO and
superoxide within the lesions creates conditions favorable for
formation of peroxynitrite, which may cause injury as a conse-
quence of protein nitration (Radi, 2004). Furthermore, high levels
of NO from macrophages also cause apoptosis of SMCs (Boyle
et al., 2002), which could promote plaque instability. It is rea-
sonable, then, to conclude that down-regulation of argI and the
FIGURE 1 | HDL promotes regression. (1) Oxidation (2) Diapedesis (3) Foam
Cell formation (4) RCT (5–6) Macrophage Egress from Lesion to Lumen and
Adventitia, respectively. HDL can inhibit processes 1–3 (red arrows) and
promote 4–6 (green arrows). Macrophage egress can occur through the
upregulation of CCR7 via activation of the sterol regulatory element binding
protein (SREBP) pathway.
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FIGURE 2 | LXRs exhibit anti-atherogenic properties. LXR ligands,
oxysterols, activate the LXR transcription factors (LXRα, LXRβ)
leading to increased expression of targets such as ABCA1 and ABCG1.
This is a key step in promoting cholesterol efflux from macrophages.
LXRs have also been shown to inhibit expression of inflammatory
mediators such as iNOS, MMP9, and IL6. Recently, it was demonstrated
that LXRα activation can induce arginase I (M2 macrophage marker)
expression suggesting that LXRs can skew macrophages toward a M2
phenotype (alternative activated, anti-inflammatory; see text for
details). In addition, we have shown that LXRs are required for
atherosclerosis regression and can induce CCR7 expression in
macrophages with the resultant egress out of the lesion. Hence, in addition
to promoting reverse cholesterol transport and having anti-inflammatory
properties, LXRs can regulate the migratory potential of macrophages in the
plaque making these transcription factors therapeutic targets against
atherosclerosis.
consequent up-regulation of NO production enhance the patho-
logical potential of the foam cells. In short, our results and these
other studies all point to argI being a candidate novel target for the
treatment of atherosclerosis. In agreement with this hypothesis,
polymorphism in the argI gene has been consistently associated
with increased frequency of myocardial infarction in humans
(Dumont et al., 2007). Recent reports suggested that members
of the PPAR family can regulate argI expression (Gallardo-Soler
et al., 2008). Given the fact that PPARs can induce LXR expres-
sion and that LXRα expression was significantly increased in the
WT recipients (Trogan et al., 2006), we wondered whether there
would be a relationship between LXR and the M2 phenotype. We
recently reported a molecular mechanism linking LXRα to the
regulation of argI via purine box factor 1 (PU.1) and interferon
regulatory factor 8 (IRF8) transcription factors (Pourcet et al.,
2011).
Recently, another model, the Reversa mouse, has given us
the opportunity to extend our studies and determine whether
the findings in the transplant model were generally applicable
to the regression process (Lieu et al., 2003; Feig et al., 2011).
Reversa mice (LDLR−/−ApoB100/100Mttpfl/flMx1Cre+/+) have
severe hypercholesterolemia and atherosclerosis as a result of
homozygosity for the LDL receptor knockout allele and an
“apoB100–only” allele. “Apo-B100–only” LDLR−/− mice have
higher LDL cholesterol levels than LDLR−/− mice on a chow
diet and develop more severe atherosclerosis than that of
apoE−/− mice (Veniant et al., 1998, 2000). The hypercholes-
terolemia, in the Reversa mouse, can be eliminated by inducing
the expression of the Mx1-Cre transgene, which inactivates the
gene for microsomal triglyceride transfer protein (Mttp) that
is required for the secretion of apoB-containing lipoproteins
(Gordon et al., 1995; Lieu et al., 2003; Feig et al., 2011). We
reasoned that the Reversa mouse could be used to study the
regression of atherosclerosis if the hyperlipidemia were reversed
later in life after plaques had developed. Using this model, we
found that reversal of hyperlipidemia led to lower levels of
CD68+ cells in plaques. Furthermore, the regression process
was characterized by reduced plaque lipid and increased con-
tent of collagen. There were also changes in plaque CD68+
cells, including (1) evidence for migratory behavior in vivo;
(2) decreased expression of genes encoding inflammatory and
prothrombotic factors; and (3) enrichment in markers of the
www.frontiersin.org July 2012 | Volume 3 | Article 286 | 7
Feig and Feig Macrophages, dendritic cells, and regression of atherosclerosis
M2 macrophage state (Feig et al., 2011). These data suggest that
there are certain features that are common to the regression
process.
Cholesterol homeostasis has also recently been investigated
with microRNAs (miRNA), which are small endogenous non–
protein-coding RNAs that are posttranscriptional regulators of
genes involved in physiological processes. MiR-33, an intronic
miRNA located within the gene encoding sterol-regulatory ele-
ment binding protein-2, inhibits hepatic expression of both
ABCA1 and ABCG1, reducing HDL-C concentrations, as well
as ABCA1 expression in macrophages, thus resulting in decreased
cholesterol efflux (Rayner et al., 2011). Interestingly, enrichment
of M2 markers in plaque CD68+ cells was observed in LDLR−/−
mice treated with an antagamir of miR-33 (Rayner et al.,
2011). The treated mice also exhibited plaque regression (fewer
macrophages and intimal area). The therapeutic potential of miR-
33 antagmirs to cause similar benefits in people was suggested
by plasma levels of HDL being raised in treated non-human
primates (Rayner et al., 2011). Thus, antagonism of miR-33
may represent a novel approach to enhancing macrophage
cholesterol efflux, raising HDL-C levels, and promoting
regression.
CONCLUSION
It is quite clear that both macrophages and DCs play important
roles in atherosclerosis. While a tremendous amount of progress
has been made in elucidating how this is so, there are still many
unanswered questions. The current evidence, however, suggests
thatmacrophages andDCs have the ability to change their inflam-
matory, metabolic, and migratory properties. The data demon-
strate that the regression of atherosclerosis is possible with factors
such as HDL, LXR, and CCR7 playing key roles (Figures 1, 2).
Ultimately, the insights gained from further experimentation will
lead to new therapeutic targets against cardiovascular disease.
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